Akash Maniam: Theranostics is Transforming Prostate Cancer Treatment, But Challenges Remain in Access and Sequencing
Akash Maniam, Medical Oncologist of Portsmouth Hospitals University NHS Trust, shared International Urology Cancer Summit’s post, adding:
“IUCS25 poll#2. The advent of theranostics has drastically changed the landscape of prostate cancer management. This great poll perfectly captures the progress we have made.
Decisions regarding sequencing, combining and of course, accessing isotopes are major challenges.
In this case, many centres won’t have access to all or most of these options. The work to bridge that gap must continue.
If we had all of them, it’s still challenging to know which to use first. We need more data in this space and better biomarkers for patient selection.”
Quoting International Urology Cancer Summit’s post:
“IUCS25 Poll #2 – Treatment sequencing in the era of Theragnostics.
This case presents a real-world scenario we all recognise –
68 year-old gentleman with mCRPC (Gleason 4+4, initial PSA 22).
Treated with docetaxel in 2018, followed by abiraterone in 2022.
Now presents with a rising PSA (35) and symptomatic, radiological bone-only progression — no visceral or nodal disease.
What would be your next step in this patient?”
More posts featuring International Urology Cancer Summit.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023